scholarly journals New opportunities in the allergic rhinitis therapy

2021 ◽  
pp. 118-124
Author(s):  
K. S. Pavlova ◽  
D. S. Mdinaradze
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Fixed Combination ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Developed Countries ◽  
Rapid Onset ◽  
Mometasone Furoate ◽  
High Efficacy ◽  
Intranasal Corticosteroids

Allergic rhinitis (AR) is one of the most common allergic diseases, especially in economically developed countries, including Russia. The main goal of AR therapy is the control achievement over the disease symptoms, the minimizing of the future exacerbations risks and side effects. Antihistamines and glucocorticosteroids are the main classes of medicines used in all allergic diseases, including AR. According to the Federal Clinical Guidelines for Allergic rhinitis the use of the intranasal corticosteroids in combination with antihistamines is recommended on the second stage of therapy and higher. Both classes of medicines have a complementary effect on the allergic inflammation pathogenesis main stages. The intranasal corticosteroids and antihistamines using allows the delivery of the medicines to the allergic inflammation area directly. Modern intranasal corticosteroids have a high affinity that provides the high efficacy in the low concentrations using and the insignificant systemic bioavailability. The review presents the key characteristics of the olopatadine and mometasone furoate nasal spray in a fixed combination, which registered in the Russian Federation recently. This combination is recommend for use in adults and children over 12 y.o. with allergic rhinitis. The pharmacological characteristics of the nasal spray components including the action mechanism described. The main clinical studies results presented, that confirmed the high efficacy and safety of olopatadine/mometasone furoate combination in AR patients. The olopatadine and mometasone furoate fixed combination ensures the rapid onset and the long-lasting effect with minimal adverse events risks that increases compliance and leads to the control achievement over the AR symptoms.

scholarly journals Treatment Evaluation with Mometasone Furoate, Alone or in Combination with Desloratadine/ Montelukast in Moderate Severe Allergic Rhinitis

2014 ◽  
Vol 60 (3) ◽  
pp. 106-108 ◽  
Author(s):  
Nona-Aura Florincescu-Gheorghe ◽  
Florica Popescu ◽  
D.O. Alexandru
Keyword(s):  
Allergic Rhinitis ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Nasal Secretion ◽  
Mometasone Furoate ◽  
Line Treatment ◽  
First Line ◽  
Nasal Symptoms ◽  
A Prospective Study ◽  
First Line Treatment

Abstract Introduction: Allergic rhinitis is one of the most common allergic diseases, characterized by the inflammation of the nasal mucosa. Eosinophils play a predominant pro-inflammatory role in allergic inflammation. This study assesses the effect of mometasone furoate alone or in combination with desloratadine/montelukast in patients with moderate-severe allergic rhinitis. Material and method: This is a prospective study that took place over 8 weeks on 70 patients diagnosed with moderate-severe allergic rhinitis with sensitization to the pollen of Ambrosia elatior. The patients were evaluated on the basis of their symptoms using the total score of nasal symptoms, the score of individual nasal symptoms and the number of eosinophils in the nasal secretion. Results: All 3 groups of patients had an improvement on the total nasal symptoms score. However, the combination of mometasone furoate with desloratadine provided statistically significant benefits on the total score of symptoms and on nasal itching as compared with mometasone furoate alone. Conclusions: The association of mometasone furoate with desloratadine should be considered first-line treatment of moderate-severe allergic rhinitis due to the benefit both on the total symptom score and on of nasal itching.

scholarly journals Allergic rhinitis from the otorhinolaryngologist’s perspective

2021 ◽  
pp. 126-132
Author(s):  
J. M. Mustafaev
Keyword(s):  
Allergic Rhinitis ◽  
Negative Impact ◽  
Allergic Inflammation ◽  
Well Being ◽  
Developed Countries ◽  
Evidence Base ◽  
Intranasal Corticosteroids ◽  
Wide Range ◽  
Allergy Treatment ◽  
Rational Therapy

Allergic rhinitis remains one of the most pressing problems of modern otorhinolaryngology. Allergic rhinitis is an allergic inflammation of the nasal mucosa characterised by the following symptoms (one or more): stuffiness, rhinorrhoea, nasal itching, sneezing. In recent years the incidence of allergic rhinitis in the economically developed countries has been shown to be close to 40–50%. Allergic rhinitis is now characterised by an early onset, often continuously relapsing course and resistance to antiallergic therapy. Allergic rhinitis has a negative impact on a person’s social and daily activities, mental well-being and general health, regardless of age. Allergic rhinitis significantly reduces job performance, physical and mental activity, communication skills, causes snoring, anxiety, depression, sleep disorders and erectile dysfunction. Studying the mechanisms of the disease provides the basis for a rational therapy that addresses the complex inflammatory response rather than just the symptoms of allergy. Treatment is either in outpatient settings or inpatient – in specialised departments. A recent priority of pharmacotherapy is the use of intranasal corticosteroids, both as basic therapy for allergic rhinitis and as part of a combined regimen. The use of intranasal corticosteroids is considered to be the therapy of choice in allergic rhinitis. The paper demonstrates the efficacy and safety of topical corticosteroids for use in clinical practice. Intranasal corticosteroids have a wide range of reported indications, an extensive evidence base and can be recommended for the treatment of allergic rhinitis. For best result intranasal corticosteroids should be used at first signs of allergic rhinitis onset.

scholarly journals The effectiveness of intranasal corticosteroids and antihistamines combination - mometasone furoate and azelastine hydrochloride nasal spray in adults with seasonal allergic rhinitis (The results of clinical trial)

2016 ◽  
Vol 13 (2) ◽  
pp. 54-64
Author(s):  
N M Nenasheva ◽  
N I Ilina ◽  
T G Fedoskova
Keyword(s):  
Clinical Trial ◽  
Allergic Rhinitis ◽  
Fixed Combination ◽  
Mometasone Furoate ◽  
Multicenter Clinical Trial ◽  
Intranasal Corticosteroids ◽  
Nasal Symptoms ◽  
Parallel Group ◽  
The Russian Federation ◽  
Intranasal Spray

Background. Intranasal corticosteroids and antihistamines are the basis of pharmacotherapy of allergic rhinitis (AR). The aim of this study was to evaluate the efficacy, safety and tolerability of Momat Rhino Advance (fixed combination of azelastine hydrochloride 140 mcg + mometasone furoate 50 mcg) intranasal spray in seasonal rhinitis patients. Materials and methods. Momat Rhino Advance was administered within 14 days in adults with seasonal AR in comparison with the original azelastine hydrochloride and mometasone furoate, used in combination with each other from separate devices against nasal (TNSS) and non-nasal (TNNSS) rhinitis symptoms. In total, 220 patients 18-65 years old with moderate/severe seasonal AR, were randomized in an open, parallel-group, multicenter clinical trial conducted in 16 centers in the Russian Federation during the period from April to September 2014. Results and conclusion. As a result of the study a marked decreasing of nasal symptoms using scale TNSS (in 89,6% relatively to the initial visit, p

scholarly journals Allergic rhinitis: the choice of rational treatment

2017 ◽  
Vol 14 (2) ◽  
pp. 71-75
Author(s):  
A V Sobolev ◽  
Ya I Kozlova ◽  
A V Pyatakova ◽  
O V Aak ◽  
N N Klimko
Keyword(s):  
Allergic Rhinitis ◽  
Clinical Practice ◽  
Nasal Spray ◽  
Second Generation ◽  
Mometasone Furoate ◽  
Rational Treatment ◽  
Intranasal Corticosteroids ◽  
Common Diseases

Allergic rhinitis (AR) is one of the most common diseases. Basic AR therapy includes both antihistamines of the second generation for per os administration in mild AR, and intranasal corticosteroids in the treatment of moderate AR. In clinical practice, oral antihistamines (in combination with intranasal corticosteroids) can be rationally replaced with intranasal antihistamines. Momate Rhino Advance nasal spray (a combination of azelastine hydrochloride and mometasone furoate) is promising medication when used as firstline therapy in the treatment of moderate and severe manifestations of AR

ESTIMATION OF EFFICIENCY AND SAFETY OF APPLICATION AQUA MARIS® ECTOIN (ANS01) NASAL SPRAY IN THE THERAPY OF ALLERGIC RHINITIS IN PREGNANT WOMEN

2019 ◽  
Vol 25 (3) ◽  
pp. 94-103
Author(s):  
M.A. Ryabova ◽  
◽  
L.V. Georgieva ◽  
Keyword(s):  
Allergic Rhinitis ◽  
Pregnant Women ◽  
Nasal Spray ◽  
Nasal Mucosa ◽  
Clinical Symptoms ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Reproductive Age ◽  
Childbearing Age ◽  
Open Label

The prevalence of allergic diseases is increasing: according to recent data, about 20% of the worlds' population suffers from allergic rhinitis. About 30% of the reproductive age women are known to suffer from allergic rhinitis, and in a third of cases, symptoms of allergic rhinitis increase during pregnancy. Allergic inflammation is the result of contact with a causative allergen and elimination of causative allergens is not always possible. The creation of a protective barrier preventing the adhesion of allergens on the surface of the nasal mucosa reduces the penetration of allergens and helps control allergic rhinitis. Aqua Maris® Nasal Spray Ectoin is a completely natural remedy that creates a physical barrier (“barrier”) for attaching allergens to the nasal mucosa and prevents the development of allergic rhinitis. Aqua Maris® Ectoin can be used for allergic rhinitis treatment in pregnant and nursing women. Non-comparative open-label trial investigating the efficacy and safety of the Aqua Maris® Nasal Spray Ectoin was carried out from September to June 2019 at the Center of early diagnosis of allergic diseases in women of childbearing age Pavlov First Saint Petersburg State Medical University. The study included 45 pregnant women with allergic rhinitis. Clinical efficacy was evaluated by the severity of clinical symptoms and rhinoscopic data of patients in dynamics during treatment. As a result of the use of Aqua-Maris Ectoin in pregnant women, a significant reduction in complaints on the 10th day of therapy and a decrease in inflammatory phenomena in the nasal cavity were observed. In addition, a significantly significant decrease in secretory nasal IgE was noted. This indicates the effectiveness of the Aqua Maris® Nasal Spray Ectoin in the treatment of allergic rhinitis in pregnant women. Adverse events associated with the use of Ectoin Aqua Maris® Nasal Spray in pregnant women were not detected. Aqua Maris® Nasal Spray Ectoin can be used for effective and safe treatment of allergic rhinitis in pregnant women.

scholarly journals CLINICAL EFFICIENCY AND ANTI-INFLAMMATORY ACTIVITYOF THERAPY IN CHILDREN WITH PERENNIAL ALLERGICRHINITIS

2010 ◽  
Vol 7 (6) ◽  
pp. 52-59
Author(s):  
V I Petrov ◽  
N V Maljuzhinskaya ◽  
I N Shishimorov ◽  
A V Razvalyaeva
Keyword(s):  
Allergic Rhinitis ◽  
Nasal Spray ◽  
Treatment Guidelines ◽  
Clinical Symptoms ◽  
Combined Therapy ◽  
Bronchial Hyperresponsiveness ◽  
Allergic Inflammation ◽  
Open Label ◽  
Old Patients ◽  
Intranasal Corticosteroids

Background. Intranasal corticosteroids and nonsedating antihistamines are the drug classes most often prescribed to treat allergic rhinitis (AR). Treatment guidelines recommend a combination of these agents for moderate to severe AR. Objective: To compare the efficacy of mometasone furoate (MF) nasal spray plus desloratadine (DL) with that of monotherapy with the individual agents in 6-16 years old patients with perennial AR. Methods. A prospective, randomized, open label, parallel group study of the efficiency of MF nasal spray plus DL and of monotherapy with MF or DL in children with persistent allergic rhinitis aged 6-16 in a 12week period was conducted. The efficacy of therapy was evaluated by level of markers of an allergic inflammation, indicators of a bronchial hyperresponsiveness and by dynamics of clinical symptoms. Results. Combined therapy (DL+MF) restores balance of cytokines: increase the Тh1 activity and decrease the Т2 activity. Combined therapy found to be effective in the majority of AR patients. Сnclusion. Combined therapy with MF and DL in the treatment of perennial AR in children has clinical advan60

ОЦЕНКА ЦИТОКИНОВОГО ПРОФИЛЯ СЫВОРОТКИ КРОВИ И СУБПОПУЛЯЦИЙ Т-ЛИМФОЦИТОВ У ДЕТЕЙ С АЛЛЕРГИЧЕСКИМИ ЗАБОЛЕВАНИЯМИ ОРГАНОВ ДЫХАНИЯ

2019 ◽  
pp. 52-60
Author(s):  
E.V. Prosekova ◽  
A.I. Turyanskaya ◽  
N.G. Plekhova ◽  
M.S. Dolgopolov ◽  
V.A. Sabynych
Keyword(s):  
Allergic Rhinitis ◽  
Bronchial Asthma ◽  
Allergic Inflammation ◽  
Allergic Diseases ◽  
Control Group ◽  
Healthy Children ◽  
Serum Cytokine ◽  
Immunological Parameters ◽  
Low Level ◽  
Level Of Significance

Расширение спектра изучаемых клонов Тхелперов определило более сложные иммунные механизмы реализации аллергического воспаления. Цель. Характеристика показателей и взаимосвязей цитокинового профиля сыворотки и субпопуляционного состава Тлимфоцитов периферической крови у детей с бронхиальной астмой и аллергическим ринитом. Материалы и методы. Проведено комплексное обследование 150 детей в возрасте 311 лет с верифицированным диагнозом бронхиальной астмы, аллергического ринита и 30 здоровых сверстников. Иммунологические параметры крови оценивали методом проточной цитометрии, концентрации интерлейкинов и IgE в сыворотке крови определяли методом твердофазного иммуноферментного анализа. При статистической обработке использовали программы Statistica 10 с критическим уровнем значимости р0,05. Результаты. У детей с аллергическими заболеваниями в сыворотке крови определены высокие уровни содержания интерлейкинов4, 8, 13, 17А, сопоставимый с показателями группы контроля уровень IL17F и низкое содержание IFNy. При бронхиальной астме и аллергическом рините у детей выявлено увеличение количества CD3CD8CD45RO, CD3CD8CD45RACD45RO Тлимфоцитов и CD3CD4 Тхелперов и повышение количество Th17 при снижении CD3CD4CD45RO клеток памяти. В группе здоровых детей популяция Th17 составляла 9,491,6, у детей с аллергическими заболеваниями количество данных клеток было значимо выше 14,50,77 (р0,001). Анализ сывороточного содержания цитокинов у детей с изолированным течением БА и в сочетании с аллергическим ринитом выявил разнонаправленные корреляции, отличающиеся по силе и направленности от таковых в группе здоровых детей. Заключение. У детей при изолированном течении бронхиальной астмы и в сочетании с аллергическим ринитом выявлены: сопоставимое с показателями здоровых детей количество CD3CD4 Тклеток, дисбаланс в субпопуляционном составе Тхелперов за счет преобладания Th2 и Th17, активация синтеза IL17A, IL4, IL8, IL13, низкий уровень сывороточного IFNy, изменения силы и направленности взаимосвязей цитокинового профиля и спектра субпопуляций Тлимфоцитов.Expansion of the range of examined Thelper clones has determined more complex immune mechanisms for the implementation of allergic inflammation. Objective. To characterize the parameters and relationships between the serum cytokine profile and Tlymphocyte subpopulation in peripheral blood of children with bronchial asthma and allergic rhinitis. Materials and methods. 150 children aged between 311 years old with bronchial asthma, and allergic rhinitis and 30 healthy volunteers were examined. Immunological parameters were assessed by flow cytometry, the concentration of serum interleukins and IgE were determined by means of enzymelinked immunosorbent assay. Statistical analysis was performed with Statistica 10 program with a critical level of significance p0.05. Results. High levels of interleukins 4, 8, 13, 17A were determined, IL7F level was not significantly different from that in control group and low level of IFNy was found in the serum of children with allergic diseases. The number of CD3CD8CD45RO, CD3CD8CD45RACD45RO Tlymphocytes, CD3CD4 Thelper cells and Th17 were increased and at the same time CD3CD4CD45RO memory cells were decreased In bronchial asthma and allergic rhinitis children. Number of Th17 cells in healthy children was 9.491.6, in allergic children it was significantly higher 14.50.77 (p0.001). Analyses of serum cytokine count in children with isolated BA and in association with allergic rhinitis revealed multidirectional correlations differing in strength and direction from those in the group of healthy children. Conclusion. In children with isolated bronchial asthma and associated with allergic rhinitis the following parameters were found: CD3CD4 Tcells count was comparable to that in healthy children, the imbalance of Thelper subpopulation: prevalence of Th2 and Th17, activation of IL17A, IL4, IL8, IL13 synthesis and low level of serum IFNy.

Sign in / Sign up

Export Citation Format

Share Document